Opendata, web and dolomites


a novel drug for prevention and treatment peripheral neuropathy symptoms

Total Cost €


EC-Contrib. €






 MP-101 project word cloud

Explore the words cloud of the MP-101 project. It provides you a very rough idea of what is the project "MP-101" about.

stop    glutamate    brain    central    supply    18m    signaling    diminishing    symptoms    metys    therapies    pharmaceuticals    6m    unpleasant    alone    difficult    substantial    nerve    nerves    trials    impeding    modulator    constant    drafted    2m    neuropathy    nervous    40    sensitization    group    prevention    endings    innovation    oncology    eurotransmitter    pain    sales    combination    people    7m    troublesome    quality    world    cancer    none    damage    painful    chemotherapy    acts    peripheral    leads    approval    treatment    drugs    excessive    sedating    big    sensory    worldwide    immuno    clinical    causing    cipn    lowering    spine    preventing    stimulation    dependent    gain    risks    scaling    regulatory    treat    performing    prematurely    agents    chain    patients    patient    chemotherapeutic    estimate    mp    fact    strength    prolonged    regardless    normal    market    diagnosed    painkiller    101    excitation    lasting    there    moderately    neuropathic    life    20181    plan    suffering    strategy    50x    submitting   

Project "MP-101" data sheet

The following table provides information about the project.


Organization address
address: GERBERGASSE 30
city: BASEL
postcode: 4001
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METYS PHARMACEUTICALS AG CH (BASEL) coordinator 50˙000.00


 Project objective

There will be over 18m new cases of cancer worldwide in 20181, out of which about 3,7m in Europe alone. Studies estimate that up to 40% of all cancer patients develop chemotherapy-induced peripheral sensory neuropathy (CIPN), meaning over 1,6m patients in EU and 7,2m world-wide may experience CIPN each year. This group is only growing in number, due to the constant growth in new cases of diagnosed cancer. The new immuno-oncology drugs are increasingly being used in combination with chemotherapy. CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms in the central nervous system, lowering the patient’s life quality and impeding patient’s normal activities. In fact, the CIPN induced pain is so strong and troublesome that many patients stop their cancer chemotherapy treatment prematurely. Regardless of the big and increasing number of people suffering from CIPN, only moderately effective therapies are available for the treatment, none specifically developed for CIPN, with substantial risks and unpleasant side effects for patients. Metys Pharmaceuticals is developing MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain. Chemotherapeutic agents damage peripheral nerve endings, causing excessive signaling and sensitization which involves the eurotransmitter glutamate: this leads to prolonged excitation of the central nerves of the spine and brain. MP-101 acts as glutamate modulator, diminishing the strength of glutamate stimulation, or, if given early enough, preventing glutamate-dependent sensitization. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. The innovation project will focus on scaling up the production by 50x, performing phase 2 clinical trials, before submitting results to gain regulatory approval for sales across Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-101" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-101" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More